Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ...
Sol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proo ...